Sclerostin Antibody Administration Increases the Numbers of Sox9creER+ Skeletal Precursors and Their Progeny

Abstract excerpt

Blocking the Wnt inhibitor, sclerostin, increases the rate of bone formation in rodents and in humans. On a cellular level, the antibody against sclerostin acts by increasing osteoblast numbers partly by activating the quiescent bone-lining cells in vivo. No evidence currently exists, to determine whether blocking sclerostin affects early cells of the osteoblast lineage. Here we use a lineage-tracing strategy...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Fibroblast Growth Factor Research
• Share to Liver physiology and pathology
• Share to Wnt/β-catenin signaling in development and cancer